Navigation Links
Soy may stop prostate cancer spread
Date:11/8/2010

CHICAGO --- Northwestern Medicine researchers at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University have found that a new, nontoxic drug made from a chemical in soy could prevent the movement of cancer cells from the prostate to the rest of the body.

These findings will be presented at the Ninth Annual American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

Genistein, a natural chemical found in soy, is being used in the lab of Raymond Bergan, M.D., the director of experimental therapeutics at the Lurie Cancer Center, to inhibit prostate cancer cells from becoming metastatic and spreading to other parts of the body. So far the cancer therapy drug has worked in preclinical animal studies and now shows benefits in humans with prostate cancer.

A recent phase II randomized study of 38 men with localized prostate cancer found that genistein, when given once a day as a pill, one month prior to surgery, had beneficial effects on prostate cancer cells.

Researchers examined the cancer cells from the subjects' prostates after surgery and found that genistein increased the expression of genes that suppress the invasion of cancer cells and decreased the expression of genes that enhance invasion.

"The first step is to see if the drug has the effect that you want on the cells and the prostate, and the answer is 'yes, it does,'" said Bergan, a professor of hematology and oncology at Northwestern University Feinberg School of Medicine and a physician at Northwestern Memorial Hospital.

The next step is to conduct another phase II study to see if the drug can stop the cancer cells from moving out of the prostate and into the rest of the body, Bergan said. If confirmed, Bergan said this could be the first therapy for any cancer that is non-toxic and targets and inhibits cancer cell movement.

"All therapies designed to stop cancer cell movement that have been tested to date in humans have basically failed have because they have been ineffective or toxic," Bergan said. "If this drug can effectively stop prostate cancer from moving in the body, theoretically, a similar therapy could have the same effect on the cells of other cancers."


'/>"/>

Contact: Erin White
ewhite@northwestern.edu
847-491-4888
Northwestern University
Source:Eurekalert

Related biology news :

1. UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer
2. Prostate cancers multiple personalities revealed
3. Vitamin E in front line of prostate cancer fight
4. Rutgers part of team awarded $3.3 million National Institutes of Health grant for prostate cancer research
5. Gene variations that alter key enzyme linked to prostate cancer
6. Atrazine causes prostate inflammation in male rats and delays puberty
7. Rutgers researchers assess severity of prostate cancers using magnetic resonance imaging
8. Mechanism for link between high fat diet and risk of prostate cancer and disorders unveiled
9. Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy
10. UNC team finds new target for treatment of advanced prostate cancer
11. Thymoquinone induced oxidative stress targets highly aggressive prostate cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... Rest of World. Annual estimates and forecasts are provided for the ... for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
(Date:2/16/2017)... ... 16, 2017 , ... EIT Digital has launched work to develop ... Pilot studies are about to get under way for the framework, which is designed ... The concept is expected to be transferred eventually to other industries that also require ...
Breaking Biology Technology: